Board of Directors

Patrick Smallcombe

Patrick Smallcombe (1963)

Elected 2021. Patrick Smallcombe, born in 1963, is a graduate of the Royal Society of Chemistry at University of South Wales and holds a Master in Business Administration from Southampton University. He is since 2019 Company Group Chairman of Johnson & Johnson in EMEA. Previously he was responsible for Johnson & Johnson's total SEA footprint and covered Janssen, Medical Device and Consumer Business. Patrick Smallcombe has also held other roles in Johnson & Johnson Asia Pacific, EMEA and North America since joining Johnson & Johnson in 2006. He also has prior experience as Managing Director of Pfizer Consumer Healthcare and Vice President, Research & Development Europe. Patrick Smallcombe is independent in relation to Karo Pharma and its management as well as in relation to the company’s major shareholders. Patrick Smallcombe does not own any shares in Karo Pharma.

Erika Henriksson

Erika Henriksson (1981)

Elected 2019. Erika Henriksson, born in 1981, has studied business administration at the Stockholm School of Economics and is, inter alia, a board member of Eton and Director at EQT Partners and has previously been a board member of AcadeMedia and Scandic Hotels Group. Erika Henriksson is independent in relation to Karo Pharma and its management, but is not independent in relation to the company’s major shareholders. Erika Henriksson does not hold any shares in Karo Pharma.

Mark Keatley (1957)

Elected 2021. Mark Keatley, born in 1957, holds a MA and MPhil from Cambridge University and an MBA from Stanford Graduate School of Business. Mark Keatley has been CFO of STADA AG and Actavis Group, two leading European manufacturers of generic and OTC medicines. He is a Board member of Recipharm AB and Neuraxpharm AG. Previously he has served as a board member of MS Pharma and Medichem, S.A., as a Senior Partner at Albrecht Prock & Partners AB, as CFO of companies in contract manufacturing, biotechnology, and natural resources, and as a Division Manager at the International Finance Corporation. Mark Keatley is independent in relation to Karo Pharma and its management as well as in relation to the company’s major shareholders. Mark Keatley does not own any shares in Karo Pharma.

Kristofer Tonström

Kristofer Tonström (1979)

Elected 2020. Kristofer Tonström, born in 1979, holds a B.Sc. (Finance) from the School of Business, Economics and Law at the University of Gothenburg and is Group CEO of Filippa K. Previously he has been, inter alia, Group CEO of Omega Pharma Nordics and General Manager Perrigo Northern Europe and has experience from eleven years in different positions at P&G. Kristofer Tonström is independent in relation to Karo Pharma and its management as well as in relation to the company’s major shareholders. Kristofer Tonström does not own any shares in Karo Pharma.

Flemming Ørnskov (1958)

Elected from 31 October 2019. Flemming Ørnskov, born in 1958, is a medical doctor with training in pediatrics and holds an MBA from INSEAD and an MPH from Harvard. He is the chairman for Recordati S.p.A and CENTOGENE and a member of the board of directors of Waters Corporation. Most recently, Flemming Ørnskov has served as the CEO of Shire Plc, and has previously held senior positions at Bayer, Merck & Co. and Novartis. Flemming Ørnskov is independent in relation to Karo Pharma and its management as well as in relation to the company’s largest shareholders. Flemming Ørnskov does not own any shares in Karo Pharma.

Uta Kemmerich-Keil

Uta Kemmerich-Keil (1966)

Elected 2020. Uta Kemmerich-Keil, born in 1966, holds a M.Sc. (Economics) from Freiburg University. Most recently she headed up the Personal Healthcare International business of P&G and has long experience from Merck KGaA, where she served, inter alia, as CEO of the global OTC- and Allergy business, EVP Finance and M&A. Uta Kemmerich-Keil is also a member of the Global Self-Care Federation and board member of Schott AG, Gothaer Versicherung AG and Röchling S.E. Uta Kemmerich-Keil is independent in relation to Karo Pharma and its management as well as in relation to the company’s major shareholders. Uta Kemmerich-Keil does not own any shares in Karo Pharma.